Company Information

CIN
Status
Date of Incorporation
14 August 1991
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
30 September 2023
Paid Up Capital
19,750,000
Authorised Capital
40,000,000

Directors

Manish Babulal Jain
Manish Babulal Jain
Beneficial Owner
over 2 years ago
Mohan Babulal Jain
Mohan Babulal Jain
Beneficial Owner
over 2 years ago
Kamala Babulal Jain
Kamala Babulal Jain
Director/Designated Partner
over 4 years ago

Past Directors

Babulal Kesharimal Jain
Babulal Kesharimal Jain
Director
almost 19 years ago

Patents

Stable Amphotericin B Microemulsion For Parenteral Use

The present invention relates to stable microemulsion composition comprising Amphotericin B alongwith suitable excipients for intravenous administration, which is capable of providing safe, stable and an efficient formulation obtained by simple and rapid process.

Injectable Composition Of Stable Paclitaxel Microemulsion

Disclosed herein is stable, microemulsion injectable composition of anti cancer drug, paclitaxel for painless intravenous and intramuscular administration with suitable excipients like appropriate solubilizer, compatible pH stabilizer, and chelating agent which are very safe and improve the dissolution of poorly sol...

Composition Of Stable Lyophilized Intravenous Administration

The present invention provides a commercially viable and stable lyophilized parenteral formulation and a method for preparing a pharmaceutical composition for intravenous administration. The invention provides lyophilized parenteral formulation comprising Rifampicin along with pharmaceutical acceptable excipients su...

Preparation Of High Purity Lornoxicam

The present invention relates to a process for the preparation of highly pure Lomoxicam. The crude Lornoxicam is reacted with solution of potassium hydroxide or potassium carbonate, sodium carbonate or sodium hydroxide, whereby high purity Lomoxicam salt is produced. This salt is subsequently converted into Lomoxica...

Process For The Preparation Of Gefitinib

Disclosed herein is a synthetic method for preparation of Gefitinib which comprises i) reacting isovanilline with hydroxylamine hydrochloride in a suitable solvent in presence of dehydrating agent to convert aldehyde group into cyano- group to obtain compound (1); reacting compound (1) with 3-Morpholino-l- chlor...

A Process For The Preparation Of N,N'' 4,10 Dioxotridecylene 1,13 Bis Tetrahydropapaverine And Its Conversion To Atracurium Besylate

Disclosed herein is a process for preparation N,N"-4,10-dioxa-3,11-dioxotridecylene-K 13-bis-tetrahydropapaverine(III), a precursor of Atracuriurn Besylate and its conversion to Atracurium Besylate, a neuro-muscular blocking agent. The novel method involving condensation of N-(2-carboxyethyl)-l-(3,4-dimethoSybenzyl)...

A Process For Preparation Of Pure Exemestane

Disclosed herein is a process for the synthesis of Exemestane involving oxidation of 6-Methyleneandrost-4-ene-3, 17-dione (11) with systematic mode of addition of DDQ in the presence of organic carboxylic acid and a buffer. Rapid adsorption-desorption column chromatography combined with recrystallisation gave pharma...

Process For The Preparation Of Gemcitabine Hydrochloride

A process for the preparation of Gemcitabine Hydrochloride (I) comprising: i) reacting 2,3-O-isopropylidene-D-glyceraldehyde and chiral auxiliary (1) by Evans and Crimmins asymmetric aldol reaction to obtain (2); ii) protecting hydroxyl group at 3’-position in compound (2) to give (3); iii) hydrolsing acetonide moie...

Process For The Preparation Of Erlotinib Hydrochloride

The present invention discloses a new improved synthetic process for the preparation of Erlotinib Hydrochloride involving 3,4-dihydroxybenzaldehyde as raw material which comprises reaction of 3,4-dihydroxybenzaldehyde with hydroxylamine hydrochloride to obtain cyano compound; which is further reacted with l-chloro-2...

Stable Propofol Microemulsion For Parenteral Delivery

Disclosed herein is stable intravenous microemulsion comprising propofol; wherein said microemulsion is characterized by comprising a surfactant, non-ionic polyoxyethylene-polyoxypropylene copolymer; a co-surfactant, non-ionic polyethylene glycol 660 hydroxystearate in a range of 0.2%-5% and 2%-25% respectively alon...

Stable Chlorambucil Oral Composition

Disclosed herein is a stable pharmaceutical compositions comprising a core containing Chlorambucil as an active ingredient and a moisture resistance coat of 2 to 4 % of total tablet weight surrounding said core comprising one or more polymers in the range of 10 to 60% and plasticizer in the range of 5 to 15% along w...

Process For Preparation Of Pipecuronium Bromide

Disclosed herein an improved process for the preparation of pure Pipecuronium bromide comprises passing of methyl bromide gas through a stirred solution of compound of formula (1) in an organic solvent at ambient temperature, followed by purification step. H,C. N CH3 (1)

Process For The Preparation Of Imatinib

Disclosed herein is a process for preparation of imatinib free base which comprises condensing 4-Methyl-N-(4-pyridin-3-yl-pyrimidin-2-yl)-benzene-l,3-diamine with 4-(4-Methyl-piperazin-l-ylmethy])-benzoic acid ester in the presence of base including organic bases and inorganic bases in an organic solvent to form ima...

A Process For Preparation Of Oxaliplatin

The present invention provides a high yielding process for the preparation of Oxaliplatin by reacting (SP-4-2)-dichloro-[(lR,2R)-l,2-cyclohexanediamine-N,N"]platinum (II) with silver sulfate in water to form more stable diaqua sulfate salt of platinum (II), followed by treating with oxalic acid. Further, the present...

An Improved Process For The Preparation Of Anastrozole

The present disclosure relates generally to an improved process for the preparation of Anastrozole, compound of formula (I). Anastrozole, compound of formula (I) is an anti-estrogenic anti-cancer drug which is used along with other medications in treatment and prevention of breast cancers. The disclosed process is f...

An Improved Process For The Preparation Of Gemcitabine Hydrochloride

The present disclosure relates generally to an improved process for the preparation of Gemcitabine Hydrochloride, compound of formula (I). Gemcitabine Hydrochloride, compound of formula (I) is a nucleoside analog and used in chemotherapy of cancers. The disclosed process is best suited for an industrial production o...

Charges

79 Crore
18 June 2009
Bank Of Baroda
22 Crore
05 February 2009
Bank Of Baroda
22 Crore
25 March 2021
Kotak Mahindra Bank Limited
35 Crore
25 March 2021
Others
0
26 April 2022
Others
0
20 January 2022
Others
0
18 June 2009
Others
0
05 February 2009
Others
0
25 March 2021
Others
0
26 April 2022
Others
0
20 January 2022
Others
0
18 June 2009
Others
0
05 February 2009
Others
0
25 March 2021
Others
0
26 April 2022
Others
0
20 January 2022
Others
0
18 June 2009
Others
0
05 February 2009
Others
0
25 March 2021
Others
0
26 April 2022
Others
0
20 January 2022
Others
0
18 June 2009
Others
0
05 February 2009
Others
0

Documents

Form DPT-3-17122020_signed
Form AOC-4(XBRL)-01122020_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-30112020
Instrument(s) of creation or modification of charge;-22092020
Optional Attachment-(1)-22092020
Form CHG-1-22092020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20200922
Form DPT-3-18092020-signed
Form CHG-1-08012020_signed
CERTIFICATE OF REGISTRATION FOR MODIFICATION OF CHARGE-20200108
Instrument(s) of creation or modification of charge;-07012020
Optional Attachment-(1)-07012020
Optional Attachment-(2)-07012020
Form MGT-7-27122019_signed
Copy of MGT-8-26122019
List of share holders, debenture holders;-26122019
Form AOC-4(XBRL)-05122019_signed
Optional Attachment-(1)-30112019
Optional Attachment-(2)-30112019
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-30112019
Form BEN - 2-31072019_signed
Optional Attachment-(2)-31072019
Optional Attachment-(1)-31072019
Declaration under section 90-31072019
Form DPT-3-05072019
Form MGT-7-13012019_signed
List of share holders, debenture holders;-28122018
Copy of MGT-8-28122018
Copy of Financial Staements duly authenticated as per section 134 (Including Boards report, auditors report and other documents)-25102018
Directors report as per section 134(3)-25102018